Pfizer Ltd. News and Updates

Name: Latest research reports of Pfizer Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Pfizer Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news on Pfizer Ltd. from all sources in a single place.

Pfizer Ltd.

17 Nov 2025

5028.50

0.53%

Pfizer brings in Rimegepant, its novel Orally Disintegrating Tablet, to treat acute migraine

Business Line

Migraine poses a challenge in India, affecting around 213 million people annually

Pfizer Ltd. is trading above its 200 day SMA of 4923.4

Pfizer launches Rimegepant ODT in India to tap $200 mn migraine market

Business Standard | 17 Nov 2025 1 more

Pfizer Ltd.

14 Nov 2025

5028.50

0.53%

Growth momentum accelerating

Buy: Pfizer Ltd.

Recommendation Target

ICICI Securities Limited

Pfizer’s Q2FY26 revenue grew at a faster pace of 9.1% YoY, surpassing IPM growth of ~8%. Rebound in growth across key brands has helped the company grow faster in the otherwise prevalent sluggish growth scenario for acute therapies.

Pfizer Ltd. is trading above its 200 day SMA of 4923.4

Pfizer Ltd.

13 Nov 2025

5028.50

0.53%

Pfizer Share Price Jumps Over 6% As Q2 Net Profit Increases

NDTV Profit

Pfizer Ltd. share price rose as much as 6.45% to Rs 5,339 apiece, the highest level since Oct 30.

Pfizer Ltd. is trading above its 200 day SMA of 4923.4

Pfizer Ltd.

08 Nov 2025

5028.50

0.53%

Metsera accepts Pfizer's $10 billion acquisition bid in ongoing M&A battle

Business Standard

Pfizer appeared to have locked up the acquisition in September before Novo jumped in last week with an unsolicited offer, sparking a strategic fight

Pfizer Ltd. is trading below its 30 day SMA of 5208.0

Pfizer Ltd.

01 Nov 2025

5028.50

0.53%

Pfizer sues to stop rival bid for Metsera by Denmark's Novo Nordisk

Business Standard

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark's Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera said the offer appeared to be superior to Pfizer's bid, which was announced in September. Metsera Inc has no products on the market, but it is developing potential oral and injectable treatments. That includes some potential treatments that could target lucrative fields for obesity and diabetes. Novo already has the treatments Wegovy and Ozempic on the market in those respective categories. Pfizer said the offer from Novo cannot be considered superior to its bid because it carries significant regulatory risk that makes it unlikely to be completed. Pfizer, which ended development of a potential pill to

Pfizer Ltd. has an average target of 6100.00 from 1 broker.

Pfizer Ltd.

09 Oct 2025

5028.50

0.53%

Pfizer-Trump deal: What it means for drug prices and pharma giants in US

Business Standard

Pfizer has pledged to make some medicines available at lower prices for the Medicaid programme and in return gained relief from immediate import tariffs

Pfizer Ltd. is trading below its 30 day SMA of 5208.0

Pfizer Ltd.

03 Oct 2025

5028.50

0.53%

Pfizer's drug-price deal with Trump follows months of negotiation deadlock

Business Standard

Pfizer and the White House were deadlocked for months over lowering US drug prices, with Trump demanding quick results from drug executives right from the start of his second term

Number of FII/FPI investors increased from 139 to 158 in Sep 2025 qtr.

Pfizer Ltd.

01 Oct 2025

5028.50

0.53%

TrumpRx, Medicaid discounts and most-favoured-nation pricing: What Pfizer's agreement means

Business Line

President Donald Trump announced a deal with Pfizer to lower US drug costs by cutting Medicaid prices and aligning new drug prices with other high-income countries. The agreement also includes Pfizer onshoring all imported pharmaceuticals to avoid US tariffs.

ICICI Securities Limited upgraded Pfizer Ltd. to Buy with a price target of 6100.0 on 14 Nov, 2025.

Pfizer strikes drug pricing deal with Trump administration, invests $70 bn in US

Business Line | 01 Oct 2025 2 more

Pfizer Ltd.

01 Oct 2025

5028.50

0.53%

Pfizer to lower prescription drug costs for Medicaid in deal with Trump

Business Standard

Drugmaker Pfizer has agreed to lower drug costs under a deal struck with the Trump administration, President Donald Trump said Tuesday, as he promised similar deals will be struck with other drugmakers facing a threat of tariffs. The announcement, which Trump made with Pfizer CEO Albert Bourla at the White House, came as the Republican president has for months sought to lower drug costs. It also came as Washington faced a federal government shutdown at midnight amid a standoff between Democrats and Republicans over health care and its costs. Under the agreement, New York-based Pfizer will charge most-favoured-nation pricing to Medicaid and guarantee that pricing on newly launched drugs, Trump said. That involves matching the lowest price offered in other developed nations. I can't tell you how big this is," the president said. I think," Bourla said, today we are turning the tide and we are reversing an unfair situation. Trump has been talking for months about the need to lower dru